Why are there inconsistencies in the outcomes of some omega-3 fatty acid trials for the management of cardiovascular disease?
Authors:
- Paramjit S TappiaPTParamjit S Tappia
- 1 February 2015
- journal article
- Published by Taylor & Francis in Clinical Lipidology
- Vol. 10 (1) , 27-32
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- OMEGA, a Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial InfarctionCirculation, 2010
- n–3 Fatty Acids and Cardiovascular Events after Myocardial InfarctionNew England Journal of Medicine, 2010
- Contribution of apolipoprotein E genotype and docosahexaenoic acid to the LDL-cholesterol response to fish oilAtherosclerosis, 2010
- Omega‐3 Dietary Supplements and the Risk of Cardiovascular Events: A Systematic ReviewClinical Cardiology, 2009
- Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- Marine-Derived n-3 Fatty Acids and Atherosclerosis in Japanese, Japanese-American, and White MenJACC, 2008
- Effect of Fish Oil on Ventricular Tachyarrhythmia and Death in Patients With Implantable Cardioverter DefibrillatorsJAMA, 2006
- Lack of benefit of dietary advice to men with angina: results of a controlled trialEuropean Journal of Clinical Nutrition, 2003
- The Inverse Relation between Fish Consumption and 20-Year Mortality from Coronary Heart DiseaseNew England Journal of Medicine, 1985
- The Diet of Canadian Indians and EskimosProceedings of the Nutrition Society, 1953